Pages that link to "Q67325396"
Jump to navigation
Jump to search
The following pages link to New antitumor antibiotics, aclacinomycins A and B (Q67325396):
Displaying 50 items.
- Antifungal anthracycline antibiotics, spartanamicins A and B from Micromonospora spp (Q28317853) (← links)
- Phase II trial of aclacinomycin A in acute leukemia and various solid tumors (Q33479596) (← links)
- Cloning and characterization of Streptomyces galilaeus aclacinomycins polyketide synthase (PKS) cluster (Q34140937) (← links)
- A gene cluster involved in nogalamycin biosynthesis from Streptomyces nogalater: sequence analysis and complementation of early-block mutations in the anthracycline pathway (Q34385347) (← links)
- Anthracycline metabolites from Streptomyces violaceus A262. I. Isolation of antibiotic-blocked mutants from Streptomyces violaceus A262. (Q34988842) (← links)
- Effects of anthracycline derivatives on hepatic neoplastic nodules of Lewis lung carcinoma and colon adenocarcinoma 26 (Q35983273) (← links)
- A comprehensive review of glycosylated bacterial natural products. (Q36029831) (← links)
- Synthesis and DNA-binding affinity studies of glycosylated intercalators designed as functional mimics of the anthracycline antibiotics (Q36345568) (← links)
- In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). (Q36467852) (← links)
- Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. An oncostatic anthracyclin that is rarely cardiotoxic and induces no alopecia (Q36477505) (← links)
- Moromycins A and B, isolation and structure elucidation of C-glycosylangucycline-type antibiotics from Streptomyces sp. KY002. (Q36924567) (← links)
- Novel derivatives of aclacinomycin A block cancer cell migration through inhibition of farnesyl transferase. (Q39202411) (← links)
- Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation (Q39331564) (← links)
- New natural products of interest under development at the National Cancer Institute (Q39542484) (← links)
- Anthracyclines—Modern tumour-inhibiting agents (Q39723489) (← links)
- Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties (Q39734481) (← links)
- Engineering anthracycline biosynthesis toward angucyclines (Q39743465) (← links)
- New cancer chemotherapy drugs in Europe (Q39793045) (← links)
- Interaction of anthracycline antibiotics with actin and heavy meromyosin (Q39876708) (← links)
- The Leeuwenhoek Lecture, 1982 - Studies of microbial products in rising to the challenge of curing cancer (Q40106903) (← links)
- NADH-dependent cinerulose reductase in rat liver microsomes (Q40157131) (← links)
- Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry (Q40413951) (← links)
- Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas (Q40765407) (← links)
- 3 Adriamycin and Related Anthracycline Antibiotics (Q41209462) (← links)
- Compartmentation of enzymes interconverting aclacinomycins in Streptomyces species AM 33352. (Q41397816) (← links)
- New Natural Products Under Development at the National Cancer Institute (Q41475049) (← links)
- Olefin cross metathesis based de novo synthesis of a partially protected L-amicetose and a fully protected L-cinerulose derivative. (Q41847043) (← links)
- Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts (Q42007942) (← links)
- Saccadic reaction-time in parietal-lobe dysfunction (Q48088752) (← links)
- Interaction of new anthracycline antibiotics with DNA. Effects on nucleic acid synthesis and binding to DNA (Q52705521) (← links)
- Low-dose aclarubicin in blastic transformation of essential thrombocythemia. (Q53498627) (← links)
- Enzymatic conversion of aclacinomycin a to Y by a specific oxidoreductase in Streptomyces (Q54570836) (← links)
- Tautomerism in 11-hydroxyaklavinone: a DFT study. (Q55373278) (← links)
- Clinical application of phorbol diester-induced leukemic cell differentiation for the definite diagnosis of acute leukemias. (Q55380400) (← links)
- Aclacinomycin A, a new anti-leukaemic agent (Q66702668) (← links)
- Anthracyclines (Q66879935) (← links)
- Antitumor anthracycline antibiotics, aclacinomycin A and analogues. II. Structural determination (Q66961355) (← links)
- Elevation of serum lipid peroxide level associated with doxorubicin toxicity and its amelioration by [dl]-?-tocopheryl acetate or coenzyme Q10 in mouse (doxorubicin, toxicity, lipid peroxide, tocopherol, coenzyme Q10) (Q66992151) (← links)
- Bohemic acid complex. Biological characterization of the antibiotics, musettamycin and marcellomycin (Q67600313) (← links)
- New anthracycline antibiotics, rhodirubins (Q67655833) (← links)
- Anthracycline induced myocardial damage. An analysis of 16 autopsy cases (Q68738599) (← links)
- Phase II evaluation of aclacinomycin-A in advanced ovarian carcinoma (Q68783137) (← links)
- Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro (Q69735783) (← links)
- Sensitive enzyme immunoassay for the quantification of aclacinomycin A using beta-D-galactosidase as a label (Q69936666) (← links)
- The influence of aclacinomycin a on the immune response and on experimental immune disorders (Q70225215) (← links)
- Determination of aclacinomycin A by reversed-phase high-performance liquid chromatography (Q70921440) (← links)
- Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study (Q70952696) (← links)
- A phase II study of aclacinomycin A in acute leukemia in adults (Q72001407) (← links)
- Auramycins and sulfurmycins, new anthracycline antibiotics: characterization of aglycones, auramycinone and sulfurmycinone (Q72018097) (← links)
- New anthracycline metabolites from mutant strains of Streptomyces galilaeus MA144-M1. I. Isolation and characterization of various blocked mutants (Q72027973) (← links)